Pivotal Phase III research evaluating the potential for the investigational antibiotic.

The compound has been formulated to treat a wide range of Gram-negative bacterial infections, which are becoming resistant to antibiotics and pose an increasing threat to public health. The addition of avibactam protects ceftazidime from becoming divided by beta-lactamases that are made by resistant bacteria. The global RECLAIM-2 and RECLAIM-1 Phase III studies both evaluated the security and efficacy of ceftazidime-avibactam, administered intravenously as a two hour infusion plus metronidazole, in comparison to meropenem, administered intravenously as a 30-minute infusion , in hospitalized adult individuals with complicated intra-abdominal infections.In contrast, only 14 of 765 U.S. Employees were found to possess MDR bacteria. Related StoriesHeart of the Rockies Regional INFIRMARY selects Aprima EHRACC's public reporting system provides information about hospitals' performanceStudy: Post hospital syndrome is normally significant risk factor for individuals undergoing elective surgeryThe higher rate of MDR bacteria among Afghans is usually partly due to the fact that they generally stay static in the hospital longer than U.S.